Genedrive PLC (GB:GDR)

LSE:GDR

GDR

Genedrive

RESEARCH TOOLSreports

Want to see GB:GDR full AI Analyst Report?

Genedrive (GDR) Price & Analysis

61 Followers

GDR Stock Chart & Stats

0.88 p

0.03 p(1.30%)

At close: Jan 09 4:00 PM EST

0.88 p

0.03 p(1.30%)

Day’s Range― - ―

52-Week Range0.19 p - 1.58 p

Previous CloseN/A

Volume280.42K

Average Volume (3M)49.58M

Market Cap

£20.87M

Enterprise Value7.74M

Total Cash (Recent Filing)£387.00K

Total Debt (Recent Filing)£500.00K

Price to Earnings (P/E)―

Beta-0.58

Next Earnings

Nov 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding1,605,568,200

10 Day Avg. Volume14,118,826

30 Day Avg. Volume49,583,488

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)5.48

Price to Sales (P/S)10.31

P/FCF Ratio-1.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables RevenueGenedrive’s business model includes recurring revenue from single-use cartridges and assay kits that run on its installed Genedrive instruments. This installed-base consumable model creates a durable, annuity-like revenue stream that can scale with placements and supports long-term margin expansion if adoption grows.

Low Financial LeverageMinimal-to-no debt materially reduces near-term refinancing and interest burdens, giving management flexibility to prioritize commercialization and product development. With low leverage the company can pursue equity, partnerships, or grants without immediate pressure from lenders, which is important during a scaling phase.

Accelerating Revenue GrowthRevenue accelerated materially in 2025, indicating improving commercial traction for the Genedrive platform and assays. If sustained, top-line growth can enable operating leverage, improve gross margin absorption across fixed costs, and reduce reliance on external funding as scale increases from current small base.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow of roughly -£5.1m in 2025 shows the business is not yet self-funding. Continued cash burn creates a structural reliance on external financing or equity issuance, raising dilution risk and constraining the company’s ability to invest opportunistically or weather setbacks.

Deep And Persistent LossesMaterial negative EBIT and net losses indicate the cost base still outstrips revenue and margins remain volatile. Persistent losses reduce retained capital for R&D and commercial expansion, and mean profitability hinges on sustained revenue growth and margin improvement that are not yet proven.

Compressed Equity BaseA sharply reduced equity base limits the company’s balance-sheet cushion and heightens the risk that future funding will require dilutive equity or onerous terms. Low equity also narrows options for raising debt and increases vulnerability to continued losses or unexpected cash needs.

Genedrive News

Genedrive Secures £0.76m R&D Tax Credit to Support Expansion of Point-of-Care Genetics

An announcement from Genedrive ( ($GB:GDR) ) is now available. Genedrive plc, a Manchester-headquartered pharmacogenetic diagnostics company focused...

45m ago

Genedrive Reports No Change in Share Option Scheme Balances in Latest Block Listing Return

Genedrive ( ($GB:GDR) ) just unveiled an update. Genedrive plc has confirmed its latest six‑monthly block listing return,...

4d ago

Genedrive Reports No Share Issuance in Latest Block Listing Return

Genedrive ( ($GB:GDR) ) has provided an update. Genedrive plc has reported its latest six-monthly block listing return,...

4d ago

Genedrive reshapes board as major shareholder joins and long-serving chairman prepares exit

Genedrive ( ($GB:GDR) ) just unveiled an announcement. Genedrive has strengthened its governance by appointing major shareholder David...

10d ago

Genedrive Test Adopted as Routine Neonatal Service at Sussex NHS Trust

Genedrive ( ($GB:GDR) ) has shared an announcement. Genedrive plc said University Hospitals Sussex NHS Foundation Trust has...

1M ago

Genedrive Positioned for NHS Tender as Rapid MT-RNR1 Test Expands Across UK NICUs

An announcement from Genedrive ( ($GB:GDR) ) is now available. Genedrive, a Manchester-headquartered pharmacogenetic testing specialist focused on...

2M ago

Genedrive Enhances Investor Hub to Deepen Shareholder Engagement

Genedrive ( ($GB:GDR) ) has shared an update. Genedrive plc has upgraded its interactive investor hub, aiming to...

2M ago

Genedrive Secures Charity-Backed Rollout of Stroke Test at Bristol’s Southmead Hospital

Genedrive ( ($GB:GDR) ) has provided an update. Genedrive plc’s CYP2C19 ID Kit is set to be implemented...

2M ago

Genedrive bolsters finances as NHS and global pilots drive uptake of rapid genetic tests

An update from Genedrive ( ($GB:GDR) ) is now available. Genedrive reported interim results to 31 December 2025,...

2M ago

Genedrive shareholders back fundraising as company expands pharmacogenetic footprint

The latest update is out from Genedrive ( ($GB:GDR) ). Genedrive plc, a Manchester‑based pharmacogenetic testing specialist, develops...

3M ago

GDR FAQ

What was Genedrive PLC’s price range in the past 12 months?

Genedrive PLC lowest share price was 0.19 p and its highest was 1.58 p in the past 12 months.

What is Genedrive PLC’s market cap?

Genedrive PLC’s market cap is £20.87M.

When is Genedrive PLC’s upcoming earnings report date?

Genedrive PLC’s upcoming earnings report date is Nov 24, 2026 which is in 172 days.

How were Genedrive PLC’s earnings last quarter?

Genedrive PLC released its earnings results on Mar 30, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.

Is Genedrive PLC overvalued?

According to Wall Street analysts Genedrive PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genedrive PLC pay dividends?

Genedrive PLC does not currently pay dividends.

What is Genedrive PLC’s EPS estimate?

Genedrive PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genedrive PLC have?

Genedrive PLC has 1,605,568,200 shares outstanding.

What happened to Genedrive PLC’s price movement after its last earnings report?

Genedrive PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.

Which hedge fund is a major shareholder of Genedrive PLC?

Currently, no hedge funds are holding shares in GB:GDR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genedrive PLC

genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.